Why the study?
Identifying predictors of no-reflow during SVG interventions is crucial to risk stratification, but the role of the atherogenic index of plasma remained unclear.
Does an elevated atherogenic index of plasma predict the no-reflow phenomenon in NSTEMI patients undergoing PCI for saphenous vein graft lesions?
Does an elevated atherogenic index of plasma predict the no-reflow phenomenon in NSTEMI patients undergoing PCI for saphenous vein graft lesions?
Elevated atherogenic index of plasma is an independent predictor of the no-reflow phenomenon in patients undergoing PCI for saphenous vein graft lesions in the setting of NSTEMI, potentially aiding in early risk stratification.
No takes yet. Share an insight, caveat, or question.
Erdoğan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: